Skip to content

JMJ PHARMA

Active Private limited companyfounded 2021active for 5 yearsRue Jules Hagnoul 1, 1350 Orp-JaucheKBO/BCE: BE 0766.337.513 #7 company by total assets in Orp-Jauche, Wholesale and retail trade sector

Lifetime

5 annual accounts with figures on one time axis
peak of €209,270 in 2023
€167,539▼ 4.1%
lowest -€34,788 in 2022
€1,900▼ 86.5%
peak of €121,597 in 2021
€111,605▲ 1.7%
€738,488▼ 6.7%
peak of 1.8 FTE in 2025
1.8 FTE▲ 5.9%
Board1 name since 2021
1 director
Documentsfilings and deeds
08-06-202653 days before the deadline
2025abbreviated format
Result from €14,028 to €1,900Cash from €8,518 to €14,950

Key points

from the 2025 annual accounts

Turnover

≈ €790,000 estimated

The accounts state no turnover.

Debts

€738,488 87% of the balance sheet
Financial debts 74%Suppliers 12%Taxes and wages 4%Other 10%

Of this, €192,549 falls due within a year.

Filings

5 annual accounts since 2021
AprilJune31 JulyOctober20222024

The last five annual accounts were filed 2 to 59 days before the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 3,273 companies had the same profile as JMJ PHARMA has now. Each dot stands for 9 companies, two years later.

94.6%
were still trading
2.6%
stopped another way
2.5%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 10 to 30%
  • a profit under 5% of the balance sheet

Another 0.3% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,273 companies, not a prediction for JMJ PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • founderdeed of 07-04-2021
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0766337513
First establishment Pharmacie Fraiture-Joos, Rue Jules Hagnoul 1, Orp-Jauche
Incorporation Founding capital of €100,000 · Founded by · 1,000 shares · appointed as director · published on 07-04-2021 · Gazette deed
All 10 events

Comparable companies

same main activity, similar in size and age
Company
JMJ PHARMA Orp-Jauche €0.9m €167,539 13.1% 1.8
PHARM TG Sambreville €1.0m €193,310 14.8% 2
PHARMACIE CAKIR DE BRESSOUX Liège €0.8m €136,708 3.1% 2
PHARMACIE KASSAR Schaerbeek €0.8m €188,778 16.6% 1.5
PHARMACIE DELDICQUE-LENFANT SRL Tournai €0.8m €244,060 25.2% 1.8
PHARMAZINNES Namur €0.9m €231,990 13.9% 1.5
PHARMACIE FERMEUSE-BRISMEE Charleroi €0.9m €220,873 -2.5% 2.5

These companies have the same main activity as JMJ PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €757,000 and €1m, founded between 2019 and 2021.

Official details

Source: KBO
Status
Active since 02-04-2021Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.316.032.6731350 Orp-Jauche, since 01-05-2021
Financial year end
31 December
Peppol
Reachable since 29-12-2025
Company details

Annual accounts 2025

€850,094▼ 5.7%
Employeeson 31-12-2025
3=
Filing
Filed on 08-06-2026, 53 days before the end of the filing period
Financials

Insights on JMJ PHARMA

JMJ PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €142,444 in 2021 to €167,539 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about JMJ PHARMA

What is the company number of JMJ PHARMA?
The company number of JMJ PHARMA is 0766.337.513. The VAT number is the same number with BE in front: BE 0766.337.513.
Where is JMJ PHARMA based?
The registered office is at Rue Jules Hagnoul 1, 1350 Orp-Jauche.Company details
What does JMJ PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of JMJ PHARMA?
JMJ PHARMA is a private limited company (BV).
When was JMJ PHARMA founded?
JMJ PHARMA was founded on 02-04-2021.
Is JMJ PHARMA still active?
Yes, JMJ PHARMA is an active enterprise in the KBO register.
How many employees does JMJ PHARMA have?
JMJ PHARMA had an average of 1.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of JMJ PHARMA?
The turnover in financial year 2025 is about €790,000. This figure is estimated from the gross margin of €167,539 and 43 comparable companies (NACE 477). It probably lies between €520,000 and €1.7m. In financial year 2022 turnover was €999,544.
Is JMJ PHARMA profitable?
In financial year 2025, JMJ PHARMA made a profit of €1,900.
Where can I find the annual accounts of JMJ PHARMA?
JMJ PHARMA filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of JMJ PHARMA due?
JMJ PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.